New long-term data for Roche ’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)

Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry visionUp to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months apartDetailed results from two global Phase III RVO studies will be presented at Angiogenesis, Exudation, and Degeneration 2024Vabysmo is approved in the US for RVO, and in more than 90 countries around the world for people living with nAMD and DMEBasel, 1 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new 72-week data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab) in macular edema due to branch and central retinal vein occlusion (BRVO and CRVO).1,2 Whereas available RVO treatments are typically given every one to two months, the data showed nearly 60% of people receiving Vabysmo in BALATON and up to 48% of people in COMINO were able to extend their treatment intervals to three or four months apart.1,2,3,4 In addition, patients in the studies maintained vision gains and robust retinal drying achieved in the first 24 weeks of the studies for more than one year. Retinal drying is an important clinical measure as swelling from excess fluid in the back of the eye has been associated with distorted and blurred vision.5 In both studies, Vabysmo was well tolerated and the safety profile was consistent with previous studies.“This is the first time that vision and anatomical improvements have been maintained for more than a ye...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news